Why insurers are dropping or changing coverage in 2026

Pharmacy budgets are straining under the cost of GLP-1 drugs, and employers and insurers are responding with tighter rules. Here's what's actually changing, why it's happening, and what to do if your coverage shifts.

Coverage for GLP-1 drugs is not being eliminated wholesale. The bar to qualify is rising, and the rules are becoming more specific. Two levers are being pulled most often.

Prior authorization requirements are getting stricter

Prior authorization, the process by which your insurer must approve a medication before it will pay for it, has always existed for most GLP-1 prescriptions. In 2026, many plans are adding new criteria, raising existing thresholds, or requiring more documentation to get that approval.

Indication-based distinctions are becoming sharper

Whether your GLP-1 is prescribed for type 2 diabetes or for chronic weight management can determine whether it's covered at all, how much you pay out of pocket, and what you have to do to get approval. These two categories are increasingly being treated very differently. Patients affected by changes do have options, but those options require active navigation. Rules vary significantly by employer size, plan type, and geography. There is no single rule that applies to everyone.

GLP-1 drugs have become a meaningful and growing share of what employers and insurers spend on prescription medications. Understanding why helps explain the decisions being made. Several factors are compounding the pressure.

These are chronic medications

Unlike a one-time treatment or a short course of antibiotics, GLP-1s are typically taken indefinitely. Costs don't just add up; they multiply year over year as more people start the medication and stay on it.

List prices remain high

Branded GLP-1 medications carry significant list prices. Negotiated rates and rebates can reduce what plans actually pay, but the underlying cost structure is substantial.

Volume is growing rapidly

Prescribing has expanded as clinical evidence has strengthened, direct-to-consumer advertising has increased, and awareness has broadened. The total number of people on these medications has risen sharply. Even if the per-person cost stayed flat, total spending would rise with volume.

A note on numbers

You may see specific figures cited elsewhere, including percentages of pharmacy budgets, year-over-year growth rates, and projected costs. These figures vary significantly depending on the source, the type of plan, and the year being measured. We've intentionally omitted specific percentages here because no single number reliably represents the full picture. The cost pressure is real and is driving real policy changes.

When an insurer or employer announces a coverage change for GLP-1 drugs, it can mean several different things. The specific type of change matters, because each one has different implications for what you'll pay and what you'll need to do.

Moving to a higher formulary tier

Formularies are the lists that insurers use to categorize drugs and assign cost-sharing levels. A drug moved to a higher tier means you pay more out of pocket, sometimes significantly more, even if coverage technically continues.

Adding or tightening prior authorization

If your plan adds a prior authorization requirement where none existed before, or raises the criteria for an existing one, your prescriber will need to submit documentation before the plan will pay. This can cause delays and, if criteria aren't met, denials.

Step therapy requirements

Some plans now require that patients try one or more lower-cost alternatives before a GLP-1 will be approved. This is sometimes called "fail first": you have to demonstrate that another approach didn't work.

Excluding weight-management indications while retaining diabetes coverage

A plan may continue covering a GLP-1 when it's prescribed for type 2 diabetes but exclude it entirely when prescribed for weight management, even if the drug is the same molecule. Not every plan is making all of these changes. Some are making none. The only way to know what applies to you is to check your specific plan documents or contact your benefits administrator directly.

This distinction deserves its own section because it's causing real confusion, and real harm, for patients who don't know it exists. The FDA has approved GLP-1 drugs under two distinct categories of indication: type 2 diabetes management and chronic weight management. These are separate regulatory approvals, and insurers treat them separately. Historically, coverage for diabetes indications has been broader and more consistent. Coverage for weight management indications has been more variable, more restricted, and, in 2026, more likely to be reduced or eliminated. The same drug can be covered under one indication and not the other. Semaglutide, for example, is approved both as Ozempic (for type 2 diabetes) and as Wegovy (for chronic weight management). A patient with type 2 diabetes prescribed semaglutide may have coverage that a patient with obesity but without diabetes does not. The diagnosis code on a prior authorization request can determine whether it's approved or denied. This is not a technicality. It's a meaningful clinical and administrative distinction that your prescriber needs to be aware of when submitting documentation. Patients with obesity but not diabetes face the greatest coverage uncertainty in 2026. If this describes you, it's especially important to understand your plan's current rules and to have a direct conversation with your prescriber about how your prescription is being coded and documented.

Prior authorization for GLP-1 drugs is not new. What's new is that the criteria are becoming more demanding, and the process is becoming more consequential. Common new or stricter criteria may include:

Documented BMI at or above a specific threshold (thresholds vary by plan)

Presence of one or more weight-related comorbidities, such as hypertension, sleep apnea, or cardiovascular disease

Proof of prior participation in a structured lifestyle intervention program

Restrictions on which type of prescriber can submit the authorization (some plans require an endocrinologist or obesity medicine specialist rather than a primary care physician)

Reauthorization is also becoming more common. Even if your initial authorization is approved, some plans now require periodic renewal, meaning you have to demonstrate ongoing benefit or continued eligibility to keep coverage. If you miss a reauthorization deadline or can't meet the criteria at renewal, coverage can lapse. If you're denied, you have the right to appeal. The appeals process typically involves your prescriber submitting additional clinical documentation explaining why the medication is medically necessary for you specifically. Timelines vary; standard appeals can take weeks, though urgent appeals may be processed faster. Your insurer is required to provide a written explanation of a denial and information about how to appeal. Your prescriber's office can often help navigate this process, and some practices have staff dedicated to prior authorization work.

For patients who lose coverage or can't meet prior authorization criteria, paying out of pocket becomes the practical alternative. This is worth understanding clearly, including both what's available and what the real limitations are.

Manufacturer savings programs

Pharmaceutical companies offer savings cards and copay assistance programs for some patients. Lilly's Zepbound savings card, for example, has offered reduced costs for eligible commercially insured patients. These programs exist and can provide meaningful savings, but eligibility requirements apply, terms change, and they are typically not available to patients with government insurance such as Medicare or Medicaid. Do not assume you qualify without verifying directly with the manufacturer.

Patient assistance programs

For patients with low incomes who meet specific eligibility criteria, manufacturers offer patient assistance programs that may provide medication at no cost or very low cost. These programs have strict income and insurance requirements. They are not a universal fallback, and eligibility is not guaranteed.

Compounding pharmacies

You may have seen or heard about compounded versions of GLP-1 drugs available at lower prices. The FDA has raised explicit safety concerns about compounded GLP-1 products, including dosing errors, improper storage, and fraudulent products that may not contain what they claim. Compounded drugs are not FDA-approved, are not equivalent to brand-name medications, and carry risks that are not present with approved products. This article does not recommend compounded GLP-1 drugs as an alternative.

Cash pay prices at retail pharmacies

If you're paying out of pocket for an approved, brand-name GLP-1, prices vary significantly by pharmacy and geography. Pharmacy discount programs and comparison tools exist, but they require active comparison shopping and prices can change. There is no single reliable cash price to quote here.

Coverage navigation is not something you should have to do alone. Here are specific questions worth raising with the people who can actually help.

Ask your prescriber

Is my prescription coded for the indication most likely to be covered under my plan?

What documentation do you have on file that would support a prior authorization or appeal?

Are there other medications in the GLP-1 class that my plan covers differently?

What are the clinical risks of stopping or interrupting this medication, and what should I watch for?

Ask your HR department or benefits administrator

What exactly changed in my formulary for 2026, and when does it take effect?

Is there an exception or appeal process, and what does it require?

Does my plan cover any GLP-1 for weight management, or only for diabetes?

Is there a preferred drug in this class that has better coverage under my plan?

Ask the manufacturer's patient support line

Do I qualify for a savings program or patient assistance program?

What documentation do I need to apply?

Are there income or insurance restrictions that would affect my eligibility?

These conversations take time, but they are the most reliable way to understand your actual situation, not a general article, not a friend's experience with a different plan.

Honest reporting requires acknowledging the limits of what's documented. The full scope of 2026 employer and insurer changes is not uniformly documented in any single source. Plans vary enormously, and employers and insurers are still implementing and communicating changes. What's true for a large self-insured employer may not apply to a small-group plan or a marketplace plan. Specific cost figures, including exact percentages of pharmacy budgets and precise year-over-year growth numbers, are not reliably sourced across plan types and have been intentionally omitted from this article. Savings program terms change. Eligibility cannot be guaranteed by any editorial source. The only way to know whether you qualify is to contact the manufacturer directly. This article reflects the state of available information at the time of writing. Coverage rules, formulary decisions, and program terms will continue to change, and your plan documents are the authoritative source for what applies to you.